Architect Of Keytruda Reflects On A Great Scientific Success Story

Keytruda will once again feature prominently at the upcoming European Society for Medical Oncology (ESMO) congress and Eric Rubin, who led the initial development of the anti-PD-1 immunotherapy marketed by Merck & Co., Inc. (known as MSD outside the US and Canada) will be in Paris to hear how the game-changing treatment is continuing to dominate the headlines eight years after its first approval.

Rubin, now senior vice president for early oncology clinical development at Merck Research Laboratories, joined the company in 2008. A couple of years later, he devised "a bold and ingenious...